35 results about "Overweight" patented technology

The present invention relates to a GLP-1- / GlP- / amylin-receptor tri-agonist having a balanced potency ratio across all three receptors and / or having improved pharmacokinetic properties. The invention also relates to pharmaceutical compositions comprising such a GLP-1- / GlP- / amylin-receptor tri-agonist as well as their use as a medicament for the treatment of subjects with overweight, obesity and associated co-morbidity.

The present invention relates to methods for treating overweight or obese in individuals in need thereof, and / or individuals with fatty liver disease or diabetes. In particular, the present invention relates to a method of treating obesity, fatty liver disease or diabetes in an individual in need thereof, the method comprising administering a SIK-3 inhibitor and a metabolic modulator to the individual.

The invention discloses a child overweight and obesity detection method and system based on multi-index cooperative determination, and the method comprises the steps: firstly deploying and initializing a special multi-mode detection tool, and inputting the basic information of a child; and then guiding the integrated device and the portable module for children to acquire physique indexes according to prompts, calling intelligent wearing behavior data, verifying the intelligent wearing behavior data, and storing the intelligent wearing behavior data into a local database of the terminal. Extracting multi-modal data, importing the multi-modal data into a built-in model, matching a WHO standard and a metabolic reference range according to age and gender, assigning differential weights according to growth stages, and correcting and outputting an obesity trend probability basic value in combination with a growth rate. The behavior data is quantified, a risk matrix is established, a cause is positioned, then a report result containing obesity probability, influence factors and early warning levels is generated through integration, and suggestions are given to abnormal children on site. And effective intervention of overweight and obesity of children is facilitated.

Disclosed herein are combinations comprising an GLP-1R agonist and an inhibitor of menin. Also described are combinations of specific GLP-1R agonists and irreversible inhibitors or reversible inhibitors of menin. Also described are methods of using the combinations for the treatment of diabetes, obesity and overweight condition.

Metabolic dysfunction–associated steatotic liver disease (MASLD), previously known as non- alcoholic fatty liver disease (NAFLD), is a condition characterized by the accumulation of fat in the liver of individuals with no alcohol consumption, and at least one cardiometabolic risk factor (overweight / obesity, high blood pressure, high blood sugar, high triglycerides levels, low HDL-C levels). The inventors demonstrated that Rab30 silencing improve metabolic dysfunction–associated steatotic liver disease (MASLD). The present invention relates to a method for the treatment of metabolic dysfunction–associated steatotic liver disease (MASLD) in a subject in need thereof comprising the administration of a therapeutically effective amount of an inhibitor of Rab30.

Provided are GIPR and GLP-1R co-agonistic polypeptides, or pharmaceutically acceptable salts, amides or esters thereof, and uses of the polypeptides, salts, amides or esters, including treatment of type II diabetes, obesity, overweight, and the like.

The invention relates to a compound comprising a GLP-1 receptor agonist and an amylin receptor agonist. The invention also relates to a pharmaceutical formulation, suitable for but not limited to oral administration, which comprises such a compound. The compound and pharmaceutical formulation comprising it may be used for the medical treatment of subjects with overweight, obesity and associated co-morbidities.

A polyhydroxyalkanoate (PHA) containing monomer units of 3-hydroxybutyrate for use, by oral administration, in the prevention or treatment of an overweight or obesity condition, or of metabolic dysfunctions related to the condition. A marked effect was observed on the reduction of the body weight, both in the case of a standard diet and in the case of a diet rich in fats, a reduction that can be attributed to an increase in lipid oxidation to the detriment of the deposit of excess lipids, as confirmed by the decrease in the body weight and by analyses of the body composition. A positive effect on the metabolic dysfunctions related to an overweight or obesity condition has also been verified, in particular on dyslipidemias, such as the blood level of low-density lipoproteins (LDL cholesterol) and triglycerides, as well as an improvement in the inflammatory state.

Methods of treating a subject having a metabolic syndrome or disease, diabetes, obesity, overweight, eating disorders, polyphagia, hyperlipidemia, insulin resistance, or methods of reducing body weight in a subject are provided. The methods involve administering to the subject a composition comprising a compound of formula I, including, for example, GAL475 (l-(2, 6-dimethylamino-8-propylamino-pyrimido [5, 4-d] pyrimidin-4-ylamino)-2-methyl-propan-2-ol), e.g., GAL475 (l-(2, 6-dimethylamino-8-propylamino-pyrimido [5, 4-d] pyrimidin-4-ylamino)-2-methyl-propan-2-ol), e.g., GAL475 (l-(2, 6- or a pharmaceutically acceptable salt, solvate, hydrate, enantiomer, stereoisomer, tautomer or isotope variant thereof, and a pharmaceutically acceptable carrier or excipient.

The application discloses a traditional Chinese medicine composition for people with obesity and overweight of spleen deficiency and damp-heat type and a preparation method thereof, and belongs to the technical field of traditional Chinese medicines. The traditional Chinese medicine composition is prepared from the following raw medicinal materials in parts by weight: Gualou 40-60 parts, Yiyiren 30-50 parts, Fuling 80-110 parts, Zhizi 10-20 parts, Renshen 1-5 parts and Huangjing 5-10 parts. The Gualou, Yiyiren and Fuling are used as monarch drugs to invigorate the spleen and eliminate dampness, the Zhizi is used as a minister drug to clear heat and drain dampness, the Renshen and Huangjing are used to tonify qi and nourish yin, support the root of spleen deficiency, and make up for the bitter cold of the Zhizi to hurt the stomach, so that the traditional Chinese medicine composition can achieve the functions of invigorating the spleen and eliminating dampness, clearing heat and tonifying qi, and treat the root and branch of the people with obesity and overweight of spleen deficiency and damp-heat type according to the pathogenesis characteristics of the spleen deficiency as the root and the damp-heat as the branch. The application has a simple formula, mild medicinal properties, and is suitable for long-term taking. The application further provides a preparation method of the traditional Chinese medicine composition, which can be prepared into a decoction, granules, capsules, tablets, pills or oral liquid, and has the advantages of simple preparation process, stable product quality and convenient taking.

The present disclosure provides methods of treating overweight or obese patients with or without type 2 diabetes mellitus. The treatment comprises administration of a dual GLP-1 receptor and GIP receptor agonist.

The present disclosure relates to a polypeptide analog or a derivative thereof, and a preparation method and use thereof, and particularly to an agonistic polypeptide analog or a derivative thereof of an insulin amyloid polypeptide receptor. The polypeptide analog or the derivative thereof provided by the present disclosure has good agonistic activity on the insulin amyloid polypeptide receptor, has the characteristics of good stability, high activity, etc. at the same time, and can be used for treating and preventing diseases related to the insulin amyloid polypeptide receptor, such as body weight abnormality, especially obesity and overweight.

The present invention provides a GLP-1- / GIP- / amylin-receptor tri-agonist having a balanced potency ratio across all three receptors and / or having improved pharmacokinetic properties. The invention also provides pharmaceutical compositions comprising such a GLP-1- / GIP- / amylin-receptor tri-agonist as well as their use as a medicament for the treatment of subjects with overweight, obesity and associated co-morbidity.

Disclosed herein is a preserved liquid pharmaceutical formulation comprising a amylin receptor agonist, a GLP-1 receptor agonist, a hydroxypropyl-substituted cyclodextrin, and one or more preservatives. The co-formulation can be used for medical treatment of subjects with: overweight or obesity, with or without associated co-morbidities; diabetes, with or without associated co-morbidities; and cardiovascular disease.

This invention relates to the field of functional food technology, specifically to a solid beverage with lipid-lowering, weight-loss, spleen-strengthening, and digestion-aiding effects, and its preparation method. The solid beverage comprises the following ingredients by weight: 2-3 parts modified sodium alginate, 5-8 parts inulin, 2-4 parts orange peel, 3-6 parts red adzuki bean extract, 1.5-3 parts cassia seed extract, 1-2 parts bitter orange flower extract, 2-4 parts radish seed extract, 3-6 parts hawthorn, and 2-4 parts lotus leaf extract. This solid beverage with lipid-lowering, weight-loss, spleen-strengthening, and digestion-aiding effects has the functions of lowering lipids, promoting digestion, weight loss, and spleen strengthening. Combined with dietary fiber such as inulin and resistant dextrin, it helps maintain intestinal function. Modified sodium alginate improves emulsification and dissolving stability. This solid beverage can be used as an auxiliary conditioning drink for overweight and hyperlipidemic individuals.

Compositions consist essentially of trigonelline or consist of trigonelline. The compositions can be used in food or beverage applications, pharmaceutical formulations, or as a dietary supplement. The compositions can be administered to a mammal to treat or prevent a mitochondria-related disease or a condition associated with altered mitochondrial function in an individual in need thereof or at risk thereof. The mitochondria-related disease or condition is selected from the group consisting of deleterious effects of aging, stress (e.g., oxidative stress), obesity, overweight, reduced metabolic rate, metabolic syndrome, diabetes mellitus, complications from diabetes, hyperlipidemia, neurodegenerative disease, cognitive disorder, stress-induced or stress-related cognitive dysfunction, mood disorder, anxiety disorder, age-related neuronal death or dysfunction, chronic kidney disease, kidney failure, trauma, infection, cancer, hearing loss, macular degeneration, myopathies and dystrophies, and combinations thereof.

The present invention relates to a nutraceutical composition for the prevention and / or treatment of obesity and / or overweight and / or the yo-yo effect in humans or animals, comprising a mixture of extracts of Chrysanthellum americanum and Hibiscus sabdariffa, or a single extract obtained from these two plants. The combination of these extracts allows for a synergistic effect that improves efficacy in regulating lipid metabolism and reducing fat accumulation in preadipocytes. Figure for the abstract: Fig. 1

The present invention relates to a GLP-1- / GIP- / amylin-receptor tri-agonist. This GLP-1- / GIP- / amylin-receptor tri-agonist may have improved pharmacokinetic properties and may be suitable for once weekly administration. The invention also relates to pharmaceutical compositions comprising such a GLP-1- / GIP- / amylin-receptor tri-agonist. The tri-agonist and pharmaceutical compositions comprising it may be used as a medicament for the treatment of subjects with overweight, obesity and associated co-morbidity.

Provided is a method for treating type 2 diabetes (T2D) using a new dosing regimen of a GLP-1 / GIP peptide, the peptide being a GLP-1 / GIP co-agonist, and provided is a method for inducing T2D remission using a new dosing regimen of a GLP-1 / GIP peptide. Also provided is a method for treating obesity using a new dosing regimen of a GLP-1 / GIP peptide. Further provided is a method for treating overweight with hypertension / obesity with hypertension using a GLP-1 / GIP peptide, the method for treating hypertension comprising a step of administering to a subject in need thereof a therapeutically effective amount of the GLP-1 / GIP peptide or a pharmaceutical composition containing same.

The present invention provides methods of treating and / or managing obesity and / or overweight and methods of losing weight, which comprise administering to a subject N-[2-{[3-ethyl-5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]-3-(2H-1,2,3- triazol-2-yl)pyridine-2-carboxamide ("Compound A"), or an enantiomer or mixture of enantiomers, a tautomer, an isotopolog, a pharmaceutically acceptable salt, solvate, hydrate, co-crystal, clathrate, or polymorph thereof, in combination with a GLP-1 receptor agonist.

An extract of Akkermansia muciniphila BAA-835 is provided, comprising: providing a bacterial culture medium containing Akkermansia muciniphila BAA-835; centrifuging the bacterial culture medium to obtain a supernatant and a precipitate; extracting a portion of the supernatant with ethyl acetate to obtain an ethyl acetate aqueous layer; drying the ethyl acetate aqueous layer to obtain an aqueous ethyl acetate extract; extracting a remaining portion of the supernatant with n-hexane to obtain a n-hexane aqueous layer and a n-hexane organic layer; and drying the n-hexane aqueous layer and the n-hexane organic layer respectively to obtain the aqueous n-hexane extract and the organic n-hexane extract. Also provided is a method of the extract as described above for treating and preventing overweight or obesity disease, increasing GLP-1, lowering triglycerides, or combinations thereof.

The present disclosure provides ALK7 binding proteins, such as anti-ALK7 antibodies and compositions and methods for making the ALK7 binding proteins. In certain embodiments, the ALK7 binding proteins inhibit or antagonize ALK7 activity. In addition, the present disclosure provides compositions and methods for diagnosing and treating diseases: overweight, obesity, diabetes, overweight, obesity, type 2 diabetes, and conditions associated therewith; metabolic disorders, as well as other diseases or conditions that can be treated, prevented, or ameliorated by targeting ALK7.

Described are pharmaceutical formulations comprising naltrexone and / or bupropion. Such pharmaceutical formulations can comprise extended-release, multilayer beads. Also described are methods of administering such formulations, such as for the treatment of overweight or obesity.

The present invention relates to a nutraceutical composition for the prevention and / or treatment of obesity and / or overweight and / or the yo-yo effect in humans or animals, comprising a mixture of extracts of Chrysanthellum americanum and Hibiscus sabdariffa, or a single extract obtained from these two plants. The combination of these extracts produces a synergy that improves efficacy in regulating lipid metabolism and reducing fat accumulation in preadipocytes.

The invention provides novel methods of treating or preventing obesity or overweight and closely associated comorbidities therewith in a mammalian subject including human.

The present invention provides a dietary food, in particular a meal replacement in the form of bars, for weight-controlling diets, said dietary food comprising 6 wt.% or less than 6 wt.% digestible and energy-providing carbohydrates, a high content of non-metabolizable carbohydrates, and a protein content from 25 wt.% to 50 wt.%. The invention further provides a method for preparing such dietary food and its use in treating diseases connected with pathological overweight.

The present invention provides compositions and pharmaceutical compositions of GPR84 agonists and GPR120 agonists for us in the treatment of obesity and overweight. The invention provides methods of treatment accordingly as well as a kit for use in the treatment of obesity and overweight.

The present invention provides a GLP-1- / GIP- / amylin-receptor triple agonist having a balanced efficacy ratio across all three receptors and / or improved pharmacokinetic properties. The present invention also provides a pharmaceutical composition comprising such a GLP-1- / GIP- / amylin-receptor triple agonist, as well as its use as a medicine for the treatment of subjects with overweight, obesity, and associated comorbidities.

The present invention relates to a pharmaceutical composition comprising a tetrahydrocannabivarin (THCV), wherein the composition further comprises cannabigerol (CBG) or cannabinodiol (CBND) or a mixture thereof, for use in the prevention and treatment of overweight, preferably associated with obesitas. The pharmaceutical composition according to the invention may further comprise the following additional compounds tetrahydrocannabinol (THC), or Cannabigerol (CBG) or Cannabinodiol (CBND) or a combination thereof.